Wilcox R G, Richardson D, Hampton J R, Mitchell J R, Banks D C
Br Med J. 1980 Aug 23;281(6239):531-4. doi: 10.1136/bmj.281.6239.531.
Ninety-eight patients with acute myocardial infarction were randomly allocated to receive sulphinpyrazone 200 mg four times daily or placebo on admission to a coronary care unit. Twenty-four-hour electrocardiogram tape recordings showed no significant reduction in serious arrhythmias in the sulphinpyrazone-treated group. In addition to the expected all in serum urate concentration, patients taking sulphinpyrazone showed a persistent increase in their serum urea and creatinine concentrations when compared with those in the placebo groups (p < 0.05 and p < 0.01 respectively). These differences could not be accounted for by differences in the extent and severity of the infarction between the two groups. These results suggest that sulphinpyrazone has no discernible antiarrhythmic effect in acute myocardial infarction.
98例急性心肌梗死患者被随机分配，在进入冠心病监护病房时，一组每日4次服用200毫克磺吡酮，另一组服用安慰剂。24小时心电图磁带记录显示，磺吡酮治疗组严重心律失常无明显减少。除了血清尿酸盐浓度如预期的那样全部下降外，与安慰剂组相比，服用磺吡酮的患者血清尿素和肌酐浓度持续升高（分别为p < 0.05和p < 0.01）。两组梗死范围和严重程度的差异无法解释这些不同。这些结果表明，磺吡酮在急性心肌梗死中没有明显的抗心律失常作用。
